The Chinese University of Hong Kong

Andrew A. Gonzalez, M.D., J.D., MPH, of the Regenstrief Institute and Indiana University School of Medicine, co-edited a draft Code of Conduct for AI use in healthcare, aiming to ensure AI's reliable and safe revolutionization of healthcare. The code, developed by the National Academy of Medicine, outlines 10 principles and 6 commitments to maximize AI's benefits while minimizing risks, focusing on equity, accuracy, and safety.

Recent advances in systemic treatments for intrahepatic cholangiocarcinoma (IHCCA) include the addition of durvalumab to gemcitabine plus cisplatin, significantly improving overall survival. Second-line therapies like fluoropyrimidine plus oxaliplatin and fluoropyrimidine plus nanoliposomal irinotecan offer options for patients without actionable alterations. Targeted agents show promise for those with specific genomic alterations. Despite progress, resistance and tumor progression within a year remain challenges, highlighting the need for further research and treatment optimization.

A CU Medicine study found urgent endoscopy within 6 hours for acute upper gastrointestinal bleeding patients doesn't lower mortality or risk of further bleeding compared to 6-24 hours. Acid suppression before endoscopy reduces need for endoscopic treatment. Findings published in NEJM.

Chinese stem cell research, initiated in the 1980s, focuses on embryonic stem cell lines, tissue stem cells, and iPS cells, aiming for clinical applications. Key labs in Beijing and Shanghai lead, with significant government investment. China established stem cell banks in 2007, advancing in basic studies and therapeutic applications, including bone-marrow transplantation and regenerative medicine. Despite progress, China lags in innovation, regulation, and quality control compared to the US and other leading countries.